282 related articles for article (PubMed ID: 38395880)
41. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
42. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
43. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
44. Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.
Byun D; Mohan S; Yoo M; Sexton C; Baylink DJ; Qin X
J Clin Endocrinol Metab; 2001 Feb; 86(2):847-54. PubMed ID: 11158056
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
Ang L; Guo L; Wang J; Huang J; Lou X; Zhao M
Cancer Lett; 2020 Jun; 479():42-53. PubMed ID: 32200038
[TBL] [Abstract][Full Text] [Related]
46. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
47. Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane.
Sun IY; Overgaard MT; Oxvig C; Giudice LC
J Clin Endocrinol Metab; 2002 Nov; 87(11):5235-40. PubMed ID: 12414897
[TBL] [Abstract][Full Text] [Related]
48. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
[TBL] [Abstract][Full Text] [Related]
49. The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis.
Zhang H; Wang J; Yin Y; Meng Q; Lyu Y
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33443534
[TBL] [Abstract][Full Text] [Related]
50. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
[TBL] [Abstract][Full Text] [Related]
51. LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer.
Li X; Hou L; Yin L; Zhao S
J Biosci; 2020; 45():. PubMed ID: 32098924
[TBL] [Abstract][Full Text] [Related]
52. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
54. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
55. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
56. Bioinformatic miRNA-mRNAs Analysis Revels to miR-934 as a Potential Regulator of the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer.
Contreras-Rodríguez JA; Puente-Rivera J; Córdova-Esparza DM; Nuñez-Olvera SI; Silva-Cázares MB
Cells; 2023 Mar; 12(6):. PubMed ID: 36980175
[TBL] [Abstract][Full Text] [Related]
57. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
58. N-3, a novel synthetic derivative of bifendate, inhibits metastasis of triple-negative breast cancer via decreasing p38-regulated FOXC1 protein stability.
Wang F; Liao R; Wang X; Xiong G; Zhang B; Li J; Wu D; Chen Y; Zhou X; Gu X; Qi Q; Li C
Biochem Pharmacol; 2023 Sep; 215():115729. PubMed ID: 37558004
[TBL] [Abstract][Full Text] [Related]
59. GDF10 inhibits proliferation and epithelial-mesenchymal transition in triple-negative breast cancer via upregulation of Smad7.
Zhou T; Yu L; Huang J; Zhao X; Li Y; Hu Y; Lei Y
Aging (Albany NY); 2019 May; 11(10):3298-3314. PubMed ID: 31147529
[TBL] [Abstract][Full Text] [Related]
60. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]